Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
3 Must-Change Settings for iPhone Clients: Safeguard Yourself ! - 2The Artemis II launch is tonight. Here's how to watch it live.
- 3'Wicked: For Good' was filmed at this surreal National Park in Egypt
- 44 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- 5What is the Insurrection Act? Can Trump really use the military to 'put an end' to Minneapolis ICE protests?
- What to know about new CDC deputy director who has been critical of COVID vaccines
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- How did I get my own unique set of fingerprints?
- The most effective method to Succeed in Your Web based Advertising Degree: Procedures for Progress
- 7 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- 6 Asian Urban areas to Visit
- Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- A Manual for Pick Dependable Vehicle Rental Administrations For 2024
- Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
